Clinical trial
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
NCT03746041 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
- Lead sponsor
- University of Rochester
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 14, 2019
- Completion date
- June 6, 2022
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myelomonocytic leukemia, myelodysplastic syndromes